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Abstract
Background: There are limited data on the potential short-term benefits associated with reductions in HbA1c levels,
and understanding any immediate improvements in health related quality-of-life (HRQoL) through better glycaemic
control may help inform diabetes management decisions. This time-trade-off (TTO) study investigated the short-
term impact on HRQoL associated with three different aspects of diabetes management; HbA1c change, body
weight change, and the complexity of treatment regimen.
Methods: The study was designed in three stages: Stage 1) Qualitative telephone interviews with people with type
2 diabetes (T2D) in Denmark who had experienced a decrease in their HbA1c level. Stage 2) A validation survey
with people with T2D in Denmark to obtain quantifiable knowledge on the short-term effects of a change in HbA1c
levels. Stage 3) TTO survey using health states based on results from stage 2. Respondents were either adults with
T2D (Sweden) or from the general public (UK and Denmark) and were separately asked to evaluate seven health
states through an internet-based survey.
Results: Results from 4060 respondents were available for the TTO analysis (UK n = 1777; Denmark n = 1799,
Sweden n = 484). ‘Well-controlled diabetes’ was associated with utilities of 0.85–0.91 and ‘not well-controlled
diabetes’ with utilities of 0.71–0.80 in all countries. Difference in utilities per HbA1c percentage point was smallest
in Sweden and largest in Denmark (between 0.025–0.034 per HbA1c percentage point respectively). The treatment
management health state associated with the lowest disutility was the once-daily insulin regimen. The disutility
associated with per kg of weight change ranged from 0.0041–0.0073.
Conclusions: Changes in HbA1c levels, insulin regimen and body weight are all likely to affect HRQoL for patients
with T2D. A change in HbA1c is likely to have a short-term impact in addition to the effect on the development of
long term diabetes complications. A treatment which has a simple regimen with fewer injections, and/or the need
for less planning, and that causes weight loss or less weight gain, compared with other treatments, will have a
positive impact on HRQoL.
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Background
The long-term effects of changes in 3-month average
plasma glucose, reflected in the HbA1c level, are well
documented for patients with diabetes [1–5]. Since
therapeutic interventions reduce HbA1c levels, there
may also be some immediate improvements in health re-
lated quality-of-life (HRQoL) related to the improved
glycaemic control e.g. reduction in symptoms such as
feeling tired or thirsty. Understanding these possible
relationships could help inform management decisions.
The majority of health economic evaluations for dia-
betes are based on the association between glycaemic
control and the risk of developing long-term complica-
tions, especially the risk for cardiovascular complica-
tions. There are very few data on health utility values for
short-term improvements in symptoms associated with
improved glycaemic control independent of long-term
complications [6].
Time trade off (TTO) is an accepted method to elicit
health related utility values for different health states.
The preference for one health state compared with
another can be quantified as the difference in elicited
utility values between the two health states, for example,
different weight effects or different treatment regimens.
While some attributes may be relatively simple to con-
vey in a health state description, such as weight change
or the number of injections per day, the short-term
effects of different levels of glycaemic control in health
state descriptions may be harder to describe in a concise
and accurate manner for the general non-diabetic popu-
lation. Conveying the short-term effects of different
levels of glycaemic control in health state descriptions
requires knowledge of the symptoms and changes in
symptoms that might be associated with changes in
HbA1c levels.
The aim of this TTO study was to investigate the
short-term impact on HRQoL associated with three dif-
ferent aspects of diabetes management; HbA1c change,
body weight change, and the complexity of treatment
regimen, using a methodology that allows comparison
between their associated health states.
Methods
The study was designed in three stages with the overall
objective to understand how changes in body weight,
multiple daily insulin injection treatment regimens and
HbA1c affect HRQoL on a daily basis. The first two
stages aimed to describe appropriate health states for
further investigation via the TTO methodology used in
stage 3.
Prior to commencing the study, diabetologists with ex-
perience with the TTO methodology were identified and
invited to form an expert steering group (ESG) to advise
at all stages of the study.
The first stage involved qualitative telephone inter-
views with people with type 2 diabetes (T2D) who had
experienced a decrease in their HbA1c level. This was
conducted to gain a preliminary understanding of the
short-term effects and experiences associated with a
drop in HbA1c, as well as confirmation of results from
previous studies about weight and regimen preferences
[7]. The outcome of this was guidance for developing
the subsequent validation survey in stage 2. The
validation survey aimed to provide clear and quantifi-
able knowledge, from a larger number of patients with
diabetes, on the short-term effects of a change in
HbA1c levels. The output from this stage was descrip-
tion of two health states; one associated with a high
HbA1c level and one associated with a low HbA1c level.
Following review by the ESG, the resulting data were
used to obtain a description of symptoms to be in-
cluded in the TTO survey (stage 3).
Stage 1 – telephone interviews
Qualitative telephone interviews were undertaken in
Denmark in May 2014 to explore the experience of indi-
viduals with T2D experiencing a decrease in HbA1c. Re-
spondents were recruited for telephone interviews in
collaboration with Steno Diabetes Center (Gentofte,
Denmark). In addition to identifying individuals who
had achieved a decrease in HbA1c, simple questions
about body weight change and treatment regimens were
included e.g. “Have you lost weight?” and “What is your
current treatment regimen?” An interview guide ensured
consistency in approach. All respondents gave informed
consent to participate.
Stage 2 – validation survey
The validation survey was conducted in Denmark in
June 2014 using an online panel of individuals with T2D
who had previously agreed to participate in internet-
based surveys. In an attempt to gain a representative
sample of the general T2D population various channels,
including telephone interviews, face-to-face interviews
and web banners, were used for recruitment. For inclu-
sion in the validation survey respondents were required
to be adults diagnosed with T2D, receiving medication,
and knowing their current HbA1c level. Respondents
were offered a nominal remuneration of less than 1€ to
compensate for their time.
Questions focused on the respondent’s last measured
HbA1c (current level) and how often they experienced
specific symptoms using ranking on a 5-point scale
(always, often, sometimes, rarely, never). The selected
symptoms were based on the results of the stage 1
telephone interviews and included; tiredness/lack of
energy; fatigue/extreme tiredness; headache; excessive
thirst; dry mouth; frequent urination during the day
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or night; blurred vision; slow healing of wounds; poor
memory; mood swings; difficulty concentrating. Psy-
chological impact of poor glycaemic control was also
measured using the validated Problem Areas in Dia-
betes 5-item scale (PAID-5) [8]. This overall method-
ology has been used to define health states in a
previous diabetes study [9].
In order to identify any changes in symptoms associ-
ated with a change in HbA1c, respondents were also
asked to recall prior HbA1c levels (previous level) either
at the time of diagnosis (treatment initiation with oral
antidiabetic agent (OAD)); at the time when they started
on insulin (basal-only insulin) or, at the time when they
progressed to bolus insulin (basal–bolus regimen) and to
recall how often they experienced the various symptoms
at this time. HbA1c levels were recorded in intervals of
0.5 % from <6 % and up to ≥12 %. Respondents report-
ing an HbA1c level above 12 % were assigned the value
of 13 % for analytical purposes. The difference between
the highest and lowest reported HbA1c levels for
those respondents reporting the greatest change were
compared, as well as the frequencies of symptoms as-
sociated with the highest and lowest HbA1c levels.
Physical and psychological symptoms were further in-
vestigated by dividing respondents into three groups
according to HbA1c change: >2 %-points, 1-2 %-
points, <1 %-point. The difference in symptom fre-
quency scores from the time with a high self-reported
HbA1c to the time of a low self-reported HbA1c was
calculated to give an impression of whether the symp-
tom was experienced more often with the high HbA1c
level than with the low HbA1c level. These compari-
sons were undertaken using descriptive statistics and
regression analysis.
Stage 3 – TTO survey
The health states used in the TTO survey were devel-
oped based on the results of the telephone interviews
and validation survey, and following review and consult-
ation with the ESG. Each symptom was evaluated for
relevance for inclusion in health state descriptions on
the basis of a significant association between the HbA1c
level and the symptom frequency. A test health state was
used to familiarise the respondents with the TTO exer-
cise, as outlined in Additional file 1: Table S1. These re-
sults were not used in the final analysis.
For change in HbA1c, two health states were developed;
‘not well-controlled diabetes’ ‘and ‘well-controlled diabetes’.
The ‘not well-controlled diabetes’ state reflected the symp-
toms of the group having experienced the highest HbA1c
levels (average 11.6 %). The ‘well-controlled diabetes’ state
reflected the symptoms of all the groups having experi-
enced any change in HbA1c with a lowest average HbA1c
level of 7.4 %. Both health states are outlined in Table 1.
For change in insulin regimen, health states were de-
veloped for ‘well-controlled diabetes’ with differences in
respect of regimen and the need for daily planning of
injection times, dose adjustment or monitoring of calorie
intake. These covered injection once-daily, injection
twice-daily, injection twice-daily including daily plan-
ning, and injection four-times-daily including daily plan-
ning (Table 2). For change in body weight, health states
were developed for ‘well-controlled diabetes’ with differ-
ent weight gains or losses; 5 kg gain, 2 kg gain, 5 kg loss
and 2 kg loss (Table 3).
Respondents were asked to evaluate seven health
states (as shown in Table 4), using TTO methodology as
previously described [10–12]. To make the trade-offs as
realistic as possible, time horizons were based on each
Table 1 HbA1c health states derived from the validation survey
Well-controlled diabetes Not well-controlled diabetes
Imagine that you have diabetes as described. Imagine that you have diabetes as described.
Imagine that you succeed in keeping your treatment
plan. Your doctor has told you that your average
blood sugar is on target. Therefore:
However, for some time you have had trouble
following your treatment plan. Your doctor has
told you that your average blood sugar is higher
than it should be. As a consequence:
• You rarely feel excessive thirst and
rarely have to urinate more often, neither
during the day nor during the night.
• You rarely drink a lot.
• A minor problem for you is feeling
scared and depressed thinking about
living with diabetes.
• Keeping your blood sugar at a good
level requires constant focus
on your lifestyle.
• You sometimes feel excessive thirst and have to urinate
more often, during both the day and the night.
• You sometimes also drink a lot.
• Sometimes you feel tired and without energy.
• A problem for you is feeling scared and
depressed thinking about living with diabetes.
• You wish your average blood sugar were lower,
but it would require several lifestyle changes and you
do not want diabetes to control your life.
Imagine what it would be like for you to live with
diabetes every day for the rest of your life.
Imagine what it would be like for you to live with diabetes
every day for the rest of your life.
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respondent’s projected life expectancy obtained using
the country, age and gender of the respondent and the
most recent World Health Organization data [13]. A
starting utility value of 0.6 was used; utility values for
each respondent were determined to a precision of 0.05.
To identify the point of indifference (i.e. when both
health state options were equally acceptable), the re-
spondents were asked the TTO question repeatedly (up
to 6 times), whilst varying the number of years living in
full health (as illustrated in Additional file 1: Figure S1).
An example TTO question, as it appeared on the screen,
is shown in Additional file 1: Figure S2.
Data were collected in Sweden, Denmark and the
United Kingdom (UK) through an internet-based survey.
In Sweden, respondents were adults diagnosed with, and
receiving medication for, T2D. In the UK and Denmark,
respondents were members of the general public. These
differences in sample collection are due to specific
requirements from the individual countries’ health
Table 2 Insulin regimen health states
Health state Description
Injection twice daily including planning • Imagine that you have well-controlled diabetes as described.
• In order to control your blood sugar level, you must give yourself two insulin injections
every day using two different pens. One injection should be taken in the morning. The
other should be taken in connection with a large meal.
• The second insulin dose should fit the type and size of your meals as well as your
activity level. Therefore you have to plan either to eat roughly the same type and size
of meals or ad- just your insulin doses every day.
• Imagine what it would be like for you to live like this every day for the rest of your life.
Injection four times daily including planning • Imagine that you have well-controlled diabetes as described.
• In order to control your blood sugar level, you must give yourself four insulin injections
every day using two different pens.
• One injection should be taken independent of meals at the same time every day.
Using the other pen you give yourself insulin injections with each of your 3 largest
meals during the day (breakfast, lunch and dinner).
• These three insulin doses should fit the type and size of your meals as well as your
activity level. Therefore you have to plan either to eat roughly the same type and size
of meals or ad- just your insulin doses accordingly.
• Imagine what it would be like for you to live like this every day for the rest of your life.
Injection once daily • Imagine that you have well-controlled diabetes as described.
• In order to control your blood sugar level, you must give yourself one insulin injection
every day.
• The injection must be taken at approximately the same time every day.
• Imagine what it would be like for you to live like this every day for the rest of your life
Injection twice daily • Imagine that you have well-controlled diabetes as described.
• In order to control your blood sugar level, you must give yourself two injections every
day using two different pens (one of which is insulin).
• Both injections must be taken at approximately the same time every day.
• Imagine what it would be like for you to live like this every day for the rest of your life.
Table 3 Change in body weight health states
Health state Description
Gain 5 kg • Imagine that you have well-controlled diabetes as described.
• The doctor changes your medication and you gain 5 kg
without changing your lifestyle.
• Imagine what it would be like for you to live like this every
day for the rest of your life.
Gain 2 kg • Imagine that you have well-controlled diabetes as described.
• The doctor changes your medication and you gain 2 kg
without changing your lifestyle.
• Imagine what it would be like for you to live like this every
day for the rest of your life.
Lose 2 kg • Imagine that you have well-controlled diabetes as described.
• The doctor changes your medication and you lose 2 kg
without changing your lifestyle.
• Imagine what it would be like for you to live like this every
day for the rest of your life.
Lose 5 kg • Imagine that you have well-controlled diabetes as described.
• The doctor changes your medication and you lose 5 kg
without changing your lifestyle.
• Imagine what it would be like for you to live like this every
day for the rest of your life.
Table 4 Health states for each respondent
Health state Each respondent evaluated
Warm-up health
state
Diabetes derived from previous work. Not used.
HbA1c Well-controlled diabetes
Not well-controlled diabetes
(The order of the two health states were randomised)
Weight 1 health state associated with weight gain (2 kg
or 5 kg randomised)
1 health state associated with weight loss (2 kg
or 5 kg randomised)
(The order of the two health states were randomised)
Regimen Two randomly selected out of the four health states
(i.e. injection twice daily including planning, injection
four times daily including planning, injection once
daily, injection twice daily
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technology assessment authorities. All respondents had
previously agreed to participate in internet-based sur-
veys and various channels were used for recruitment to
attempt to gain a representative internet panel. Only
individuals aged ≥18 years were approached and took
part at their discretion; anonymity was preserved
throughout. As with the validation survey, respondents
were offered a nominal remuneration of less than 1€ to
compensate for their time. The functionality of the
questionnaire was validated in a pilot study. In addition
to questions related to the TTO exercise, respondents
provided data on demographics and employment status.
Respondents with diagnosed diabetes were also asked
to provide further information regarding the duration
of their diabetes and their current medication regimen.
Respondents who chose not to trade any lifetime (i.e.
preferred to live in the health state described rather than
in full health in all TTO questions, illustrated in
Additional file 1: Figure S1), or were willing to trade a
very high proportion of their remaining lifetime to be re-
stored to full health (i.e. preferred to live in full health in
all TTO questions, illustrated in Additional file 1: Figure
S1, were carefully investigated. Such respondents were
excluded if they refused to trade time on ethical or reli-
gious grounds, or if they did not understand the ques-
tions. However, those who believed the health state
manageable or who stated desire to live as long as pos-
sible due to obligations (e.g. caregivers) were retained.
Statistical analysis
All statistical analyses were performed using SAS® (ver-
sion 9.4) statistical software. A utility value was assigned
to each health state based on each individual response,
derived from the midpoint of the indifference interval.
The average utility value was calculated for each health
state, and utility differences for the relevant health states
were calculated.
As the response distribution was unknown but sus-
pected to be non-normal, non-parametric bootstrapping
was used to simulate standard errors and confidence
intervals (CIs) for the mean TTO values. This method
estimates the parameter’s distribution by repeatedly
resampling the original data set with replacement
[14–16]. A total of 10,000 iterations were performed.
The difference between utility values for health states
was deemed to be significantly different from zero if the
confidence intervals obtained by bootstrapping around
this difference remained above zero.
In the main analysis those with the 2.5 % lowest and
the 2.5 % highest utility differences were excluded. This
objective cut-off was chosen as a way to increase stabil-
ity of the results without having to apply different sub-
jective cut-off points for each of the three health states.
Sensitivity analyses were also undertaken applying differ-
ent cut-off criteria.
Estimation of HRQoL impact per HbA1c point
The results of the validation study suggested that the
greater the reduction in HbA1c, the greater the effect
on symptom frequency in the health states. A signifi-
cant association was seen between changes in HbA1c
levels and changes in all physical and the majority of
the psychological short-term symptoms included in
the TTO health states.
To allow interim utility values to be derived, an as-
sumption was made that utility changes were linear be-
tween the ‘not-well controlled’ and ‘well controlled’
health states, defined by a 4.2 % difference in HbA1c
(11.6 %–7.4 %). Therefore the utility difference between
health states for each individual was divided by 4.2 to
calculate the average increase in utility per HbA1c
percentage-point change.
As the 4.2 % difference was derived from self-reported
HbA1c levels stated in interval categories (with censor-
ing at each end), sensitivity analyses were also per-
formed using various different cut-off criteria and
applying uncertainty in the HbA1c difference between
the two health states.
Estimation of HRQoL impact from insulin regimen features
The impact on HRQoL of different insulin regimens was
derived by calculating the difference in utility between
the insulin regimen health states and well controlled
diabetes. The resulting difference in values thus reflects
the effect of the changed feature in treatment regimen
description alone, with no confounding influence from
the estimated disutility associated with having diabetes.
Estimation of HRQoL impact of body weight changes
The impact on HRQoL due to body weight changes was
derived by calculating the difference in utility between
each of the two weight-related health states presented to
each respondent. Each respondent evaluated two of four
different health states for body weight; one implying
weight loss of either 2 kg or 5 kg and another implying
weight gain of either 2 kg or 5 kg.
Subsequently, an average utility per kilogram weight
change was calculated and in the same way, the utility
per change in BMI units was also derived.
Results
Stage 1 – telephone interviews
In total, eight individuals with T2D who had experienced
a drop in HbA1c completed telephone interviews (88 %
male and average age of 72 years). Results of the tele-
phone interviews confirmed that even though patients
aspire to lose weight, most were not willing to change
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their lifestyle to obtain weight loss. Examples of short-
term symptoms that might be associated with high
HbA1c levels such as thirst, dryness of the mouth, in-
creased urination (both volume and frequency), tiredness
(ranging from little to extreme) and psychological issues
were identified for inclusion in the validation survey.
Stage 2 – validation survey
A total 268 out of 298 respondents could recall both
their current and previous HbA1c levels. The majority of
respondents were male (72 %), with average age of 66.5
(7.7) years and average 11 years (6.9) duration of dia-
betes. The average current HbA1c level was 7.5 %. The
average change in HbA1c was 2.0 %-points. Respondents
who had experienced a change in HbA1c of >2 %-points
had an average high HbA1c of 11.6 %. The average low-
est HbA1c for all respondents having experienced a
change was 7.4 %; thus giving a difference of 4.2 %-point
(11.6 %–7.4 %) between these two groups.
The association between changes in the frequency of
experiencing symptoms and change in HbA1c levels was
significant for the majority of symptoms, as outlined in
Table 5 and detailed in Additional file 1: Figure S3–S8.
Stage 3 – TTO survey
Total number of respondents was 2159 in the UK, 2420
in Denmark and 723 in Sweden. Of these, valid re-
sponses were available from 1777 respondents in the
UK, 1799 respondents in Denmark and 484 respon-
dents in Sweden. Responses were excluded from 1242
respondents, either because they were only partly
complete (n = 702), respondents refused to trade on
ethical or religious grounds (n = 316), or if respondents
failed a test question (i.e. those who preferred living a
shorter time with diabetes than living for longer in full
health) (n = 224). The profile of respondents included
in the final sample is given in Table 6.
HbA1c health states
The results for the utility values of the two HbA1c health
states are presented in Fig. 1. As expected, ‘well-con-
trolled diabetes’ was associated with higher utility than
‘not well-controlled diabetes’ in all countries with the
difference being significantly different from zero (UK
0.139, 95 % CI 0.132, 0.147; Denmark 0.141, 95 % CI
0.134, 0.149; Sweden 0.106, 95 % CI 0.094, 0.119). In
Sweden, however, respondents evaluated both health
states with higher utility compared to the respondents in
the UK and Denmark. The difference between the values
for both health states was also smaller in Sweden. The dif-
ference in utilities per HbA1c percentage point (Table 7)
was smallest in Sweden and largest in Denmark (utility
difference between 0.025–0.034 per HbA1c percentage
point respectively).
Sensitivity analysis showed that the results were not
overly sensitive and that the cut-off values used were ap-
propriate (Table 8).
Table 5 Results from the validation survey for the association between change in HbA1c levels and change in frequency of
short-terms symptoms
Symptom Results
Excessive thirst Significant association between change in the frequency of experiencing excessive thirst and change in
HbA1c (p < 0.0001).
Frequent urination (day and night) Significant association between change in the frequency of experiencing frequent urination and change
in HbA1c (p < 0.0001, p = 0.0005 for day and night respectively)
Fatigue/extreme tiredness and tiredness
and lack of energy
Significant association between change in the frequency of experiencing fatigue symptoms and change
in HbA1c (p < 0.0001 and p = 0.0001 for tiredness/lack of energy and fatigue/extreme tiredness respectively).
Psychological
Feeling scared when thinking about living
with diabetes
Significant association between feeling scared…” and change in HbA1c (p = 0.0328). The p value for the
association between “feeling depressed…” and change in HbA1c was p = 0.0557.
Feeling depressed when thinking about
living with diabetes
Wishing to reduce HbA1c The higher the current HbA1c level, the more the respondents wanted to reduce their HbA1c
level (p < 0.0001).
Table 6 Final sample respondents’ profile
UK Denmark Sweden
N = 1777a N = 1799a N = 484b
Male (%) 50 50 63
Age, years (mean) 43.5 (14.5) 45.5 (15.8) 63.8 (9.2)
BMI kg/m2 (mean) 26.1 (5.7) 26.2 (5.4) 30.1 (5.3)
Treatment with oral
anti-diabetic drugs (%)
- - 87 %
Insulin treatment (%) - - 34 %
Diabetes duration, years (mean) - - 9.5 (7.0)
Duration of insulin treatment
(mean years)
- - 7.5 (6.6)
Currently employed (%) 59 52 31
aSample of the general population bAdults with Type 2 diabetes
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Insulin regimen health states
Results for the different insulin regimens compared to
the health state ‘well controlled diabetes’ are shown in
Fig. 2. In all three countries, the health state associated
with the lowest disutility (the best health state) was the
once-daily insulin regimen. Regimens with additional in-
jections and/or patients having to plan around injections
and meal-times increased the disutility. The health state
with the highest disutility (the worst health state) was
the basal–bolus health state with four daily injections
and the associated planning. In Denmark, the difference
between the once-daily insulin regimen health state and
‘well controlled diabetes’ was not significantly different
from zero (−0.01, 95 % CI −0.012, −0.003).
Selected differences between the four different regi-
men health states (Table 7) suggested that one additional
injection (without planning) was valued in the range of
0.015–0.021. Additional planning with a twice daily in-
jection regimen reduced the utility value by between
0.022–0.026. Furthermore, the difference between a
basal–bolus regimen of four injections and once-daily
planned regimen was valued between 0.070–0.109. The
basal–bolus regimen had the greatest negative impact on
HRQoL compared with the other regimens.
Body weight health states Figure 3 illustrates the util-
ities assigned to the four body weight health states. As
expected, results in all three countries suggested that re-
spondents would prefer to lose rather than gain weight.
Gaining 5 kg was valued in the range of 0.80–0.84
whereas gaining 2 kg was valued in the range of 0.84–


















Fig. 1 Utilities for well-controlled and not well-controlled diabetes health states. The error bar denotes the 95 % confidence interval derived
from bootstrapping




















HbA1c change (per percentage point) 0.033 0.031 0.035 0.034 0.032 0.035 0.025 0.022 0.028
Weight change
Per kg 0.0073 0.0065 0.0081 0.0041 0.0036 0.0046 0.0068 0.0057 0.0081
Per BMI-unit 0.021 0.018 0.023 0.012 0.011 0.014 0.021 0.017 0.024
Insulin regimen
Once daily vs twice daily 0.020 0.010 0.031 0.021 0.014 0.027 0.015 0.0001 0.029
Once daily vs twice daily planning 0.046 0.035 0.058 0.043 0.036 0.051 0.038 0.021 0.054
Once daily vs four times daily planning 0.070 0.057 0.082 0.084 0.075 0.093 0.109 0.086 0.133
Twice daily vs twice daily planning 0.026 0.014 0.037 0.022 0.015 0.030 0.023 0.006 0.040
Twice daily vs four times daily planning 0.049 0.037 0.062 0.064 0.055 0.072 0.095 0.071 0.118
Twice daily planning vs four times daily
planning
0.023 0.010 0.037 0.041 0.031 0.051 0.071 0.047 0.096
aSample of the general population bAdults with Type 2 diabetes
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0.88. The ranges for losing 5 kg and losing 2 kg were
similar (0.87–0.92 and 0.88–0.92 respectively).
The consolidated results by country are detailed in
Table 7.
Discussion
This study aimed to quantify the short-term HRQoL im-
pact associated with change in three different aspects of
diabetes management; HbA1c level, weight change, and
the complexity of treatment regimen using TTO meth-
odology. TTO produces valuations based on decisions
made under conditions of certainty and is an accepted
method for preference valuations of health states by
various health-technology assessment bodies (e.g. Na-
tional Institute for Health and Care Excellence in the
UK). In this TTO study, the trade-offs were individually
based on the respondents’ age and life-expectancy, which
may increase the relevance of the methodology and
avoid some of the disadvantages of the fixed 10- or 30-
year horizon used in other studies [11, 17].
Our results for HbA1c showed a significant association
between change in HbA1c and frequency of experiencing
hyperglycaemia related symptoms (frequent urination
and excessive thirst). As expected, well-controlled dia-
betes was associated with higher utility than not well-
controlled diabetes.
The difference between the two health states was signifi-
cantly different from zero for each of the three countries;
the population with diabetes from Sweden valued both
health states higher (better) than the general populations
from the UK and Denmark. Similar results have been ob-
served in other studies [6] and suggest that people with
experience of a disease give less value to its associated im-
pacts on HRQoL than those who do not have the disease.
The population with diabetes were also older on average
(63.8) than the general populations from UK (43.5) and
Denmark (45.5) which may have also influenced percep-
tions of HRQoL. There were also small differences be-
tween the values for the UK and Denmark which may
have many causes, for example differences in each health
care system and the way diabetes is viewed by society.
Only two previous studies have analysed the relationship
between HbA1c levels and short term effects on HRQoL
in T2D [18, 19]. Peyrot et al. [18] investigated the relation-
ship between HbA1c levels and HRQoL measured by the
EQ-5D in adults with T2D and showed that a change in
HbA1c of −1.20 % was associated with an improvement in
health utility of 0.03 (95 % CI 0.00, 0.07); our results are
very similar with a 1 % change in HbA1c being associated
with an improvement in health utility of 0.025 in those re-
spondents with T2D. The study by Koopmanschap [19]
also found an association between HbA1c and health util-
ity in T2D although no direct estimate was reported in
this study. A recent study by McQueen et al. [6] also
found similar utility values (1 % increase in HbA1c was
associated with a disutility of −0.03 [95 % confidence
Table 8 Sensitivity analyses of HbA1c difference between health states “well-controlled” and “not well-controlled” diabetes using
different cut-off criteria
2 %, 5 % and 10 % cut off criteria Different cut-off criteria (2.5 % cut off)
2 % cut off 5 % cut off 10 % cut off Diff. 3.5 % Diff. 4.2 % Diff. 4.7 %
UK 0.144 0.139 0.130 0.038 0.033 0.029
Denmark 0.147 0.141 0.131 0.038 0.034 0.025
Sweden 0.110 0.106 0.098 0.029 0.030 0.023





























Fig. 2 Disutility associated with insulin regimen compared to well-controlled diabetes. Error bars denote 95 % confidence intervals
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interval [CI]-0.049, −0.006]) for association between
HbA1c and health utility in T1D.
Several studies have shown that a complex treatment
regimen can negatively impact adherence [20–22]. We
aimed to substantiate data on the potential effects of
complex insulin injection regimens in this study by look-
ing at how these can affect HRQoL. Our results confirm
that regimen has an impact on HRQoL and again, the
respondents with diabetes in Sweden gave a higher value
to each health state than the respondents from the
general population in the UK and Denmark. The basal–
bolus regimen had the greatest impact on HRQoL; the
difference between a basal–bolus regimen of four injec-
tions and a once-daily planned regimen was 0.102
(0.007–0.109). Our results are similar to those reported
recently in a TTO study designed to assess the HRQoL
impact of flexible basal insulin doses [23]. The result
showed that in the general population time-flexible basal
insulin injections were associated with 0.016 and 0.013
higher utility compared with a fixed time of injection for
basal-only and basal–bolus regimens, respectively.
Once-daily injections also had higher utility compared
with twice-daily injections for basal (0.039 and 0.042)
and basal–bolus (0.022 and 0.021) regimens, for the gen-
eral population and for those with diabetes, respectively.
Diabetes medications differ with respect to anticipated
changes in body weight and we were interested to see
how weight gain and weight loss may affect HRQoL.
Our results suggest that the utility value per kg of body
weight is largest when comparing weight gain of 5 kg
with weight loss of 2 kg. The impact is higher than the
combination of weight loss of 5 kg compared to weight
gain of 2 kg implying that avoiding weight gain is more
important than weight loss. These results are in align-
ment with other similar studies [24–26]. A recent study
that aimed to estimate utility values for hypothetical
health states associated with differences in weight and
quality of life in Canadians with T2D showed for every
decrease of 1 kg/m [2] BMI there was an associated
increase in utility of 0.0171 (95 % CI: 0.0103, 0.0238)
[26]. Our study showed a utility of 0.021 for each BMI
unit lost in those respondents with T2D.
The key limitation of the methodology is the assump-
tion that utility values change linearly as HbA1c and
weight changes. This assumption allows the calculation
of interim utility values and was made based on consult-
ation with the clinical experts. Further limitations in-
clude those associated with internet-based surveys.
Web-based methodology means that help cannot be
offered if respondents have queries and with a lack of
supervision, there is also a risk that some respondents
may not spend adequate time considering their answers.
We sought to minimise this through the survey design,
ensuring a 10-s delay before proceeding to the next
question. Additionally, the use of an internet-based sur-
vey may pose a selection bias, since only literate respon-
dents with internet access can participate. However, the
literacy rates and proportion of internet users in the
three countries is high [27]. The potential for a long re-
call period in the study could also affect the accuracy of
respondent reporting of symptoms. Lastly, by offering
incentives to participate there is a risk of bias, however,
the remuneration offered was small (<€1).
Conclusion
Based on reported preference for different health states,
these results suggest that changes in HbA1c levels, insu-
lin regimen and body weight are all likely to affect
HRQoL for patients with diabetes. Furthermore, a
change in HbA1c is likely to affect some aspects of daily
living in addition to the effect on the development of
long term diabetes complications. These results suggest
that a treatment which has a simple regimen with fewer
injections, and/or the need for less planning, and that


















Fig. 3 Utilities for weight gain or loss health states. Error bars denote 95 % confidence intervals
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causes weight loss or less weight gain, compared with
other treatments, will have a positive impact on HRQoL.
Additional file
Additional file 1: Table S1 and Figures S1-S8. (DOCX 622 kb)
Competing interests
This study was funded by Novo Nordisk. MMTJ and AE are employees and
shareholders of Novo Nordisk. MB and HHJ both received funding from
Novo Nordisk to perform the analyses. JJ has participated in Novo Nordisk
advisory boards and received honoraria for lectures. MR is an employee of
Steno Diabetes Center, a non-profit company which is owned by Novo Nor-
disk. ME has received research awards from Novo Nordisk, Novartis and
Takeda, honoraria from Novo Nordisk, Novartis, Takeda, MSD, Eli Lilly and par-
ticipated in advisory boards for Novo Nordisk, Novartis and MSD.
Authors’ contributions
All authors participated in the design of the study. MMTJ, AE, HHJ and MB
participated in the analysis. MMJ and AE led the development of the
manuscript, and all authors have reviewed and approved the draft and
final versions.
Acknowledgements
Editorial support and data checking were conducted by Adelphi Values Ltd,
with funding from Novo Nordisk.
Author details
1Steno Diabetes Center, Gentofte, Denmark. 2University Hospital Llandough,
Cardiff, UK. 3Incentive, Holte, Denmark. 4Novo Nordisk, Søborg, Denmark.
5Novo Nordisk, Malmö, Sweden. 6Faculty of Health Sciences and Medicine,
Örebro University, Örebro, Sweden. 7Endocrine and Diabetes Center, Karlstad
Hospital, Karlstad, Sweden.
Received: 9 July 2015 Accepted: 9 January 2016
References
1. Group UPDSU. Intensive blood-glucose control with sulphonylureas or
insulin compared with conventional treatment and risk of complications in
patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.
2. UPDSU Group. Effect of intensive blood-glucose control with metformin on
complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet. 1998;352(9131):854–65.
3. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al.
Association of glycaemia with macrovascular and microvascular
complications of type 2 diabetes (UKPDS 35): prospective observational
study. Br Med J. 2000;321(7258):405–12.
4. Group TDCaCTR. The effect of intensive treatment of diabetes on the
development and progression of long-term complications in insulin-
dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.
5. Group UPDS. Quality of life in type 2 diabetic patients is affected by
complications but not by intensive policies to improve blood glucose or
blood pressure control (UKPDS 37). Diabetes Care. 1999;22(7):1125–36.
6. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Libby AM, et al.
Association between glycated hemoglobin and health utility for Type 1
diabetes. Patient. 2014;7(2):197–205.
7. Bøgelund M, Vilsbøll T, Faber J, Henriksen JE, Gjesing RP, Lammert M.
Patient preferences for diabetes management among people with type 2
diabetes in Denmark-a discrete choice experiment. Curr Med Res Opin.
2011;27(11):2175–83.
8. McGuire B, Morrison T, Hermanns N, Skovlund S, Eldrup E, Gagliardino J,
et al. Short-form measures of diabetes-related emotional distress: the
Problem Areas in Diabetes Scale (PAID)-5 and PAID-1. Diabetologia. 2010;
53(1):66–9.
9. Harris SB, Khunti K, Landin-Olsson M, Galbo-Jørgensen CB, Bøgelund M,
Chubb B, et al. Descriptions of health states associated with increasing
severity and frequency of hypoglycemia: a patient-level perspective. Patient
Prefer Adherence. 2013;7:925–36.
10. Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev
Pharmacoecon Outcomes Res. 2002;2(2)99–108.
11. Dolan P, Gudex C, Kind P, Williams A. The time trade‐off method: Results
from a general population study. Health Econ. 1996;5(2):141–54.
12. Robinson A, Dolan P, Williams A. Valuing health status using VAS and TTO:
what lies behind the numbers? Soc Sci Med. 1997;45(8):1289–97.
13. World Health Organization. Life tables for WHO member states. Geneva:
WHO; 2014.
14. Chang WT, Collins ED, Kerrigan CL. An Internet-based utility assessment of
breast hypertrophy. Plast Reconstr Surg. 2001;108(2):370–7.
15. Atkinson SE, Wilson PW. Comparing mean efficiency and productivity scores
from small samples: a bootstrap methodology. J Prod Anal. 1995;6(2):137–52.
16. Efron B. Nonparametric estimates of standard error: the jackknife, the
bootstrap and other methods. Biometrika. 1981;68(3):589–99.
17. Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-
severe hypoglycaemia elicited from persons with and without diabetes in
Canada and the United Kingdom. Health Qual Life Outcomes. 2008;6:1–8.
18. Peyrot M, Rubin RR, Chen X, Frias JP. Associations between improved
glucose control and patient-reported outcomes after initiation of insulin
pump therapy in patients with type 2 diabetes mellitus. Diabetes Technol
Ther. 2011;13(4):471–6.
19. Koopmanschap M, Board C-A. Coping with Type II diabetes: the patient’s
perspective. Diabetologia. 2002;45(7):S18–22.
20. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence
behaviours and barriers in the multinational Global Attitudes of Patients and
Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682–9.
21. Rubin RR. Adherence to pharmacologic therapy in patients with type 2
diabetes mellitus. Am J Med. 2005;118(Suppl 5A):27s–34s.
22. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication
dosing frequency on adherence in chronic diseases. Am J Manag Care.
2009;15(6):e22–33.
23. Evans M, Jensen HH, Bøgelund M, Gundgaard J, Chubb B, Khunti K. Flexible
insulin dosing improves health-related quality-of-life (HRQoL): a time trade-
off survey. J Med Econ. 2013;16(11):1357–65.
24. Kiadaliri A, Gerdtham U-G, Eliasson B, Gudbjörnsdottir S, Svensson A-M,
Carlsson K. Health Utilities of Type 2 Diabetes-Related Complications:
A Cross-Sectional Study in Sweden. Int J Environ Res Publ Health.
2014;11(5):4939–52.
25. Bagust A, Beale S. Modelling EuroQol health-related utility values for
diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217–30.
26. Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on
utilities of differences in body weight among Canadian patients with type 2
diabetes. Curr Med Res Opin. 2014;30(7):1267–73.
27. Central Intelligence Agency. The World Factbook 2012. Washington, DC:
Government Printing Office; 2012.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ridderstråle et al. Health and Quality of Life Outcomes  (2016) 14:13 Page 10 of 10
